Twist Bioscience Co. (NASDAQ:TWST) Given Average Recommendation of “Buy” by Brokerages

Twist Bioscience Co. (NASDAQ:TWST) has been assigned an average rating of “Buy” from the eight analysts that are covering the firm, Marketbeat Ratings reports. Eight analysts have rated the stock with a buy rating. The average twelve-month price objective among brokerages that have issued ratings on the stock in the last year is $46.63.

A number of equities analysts have recently commented on the stock. Guggenheim assumed coverage on shares of Twist Bioscience in a report on Tuesday, June 4th. They issued a “buy” rating and a $53.00 price target on the stock. Evercore ISI increased their price target on shares of Twist Bioscience from $46.00 to $50.00 and gave the stock an “outperform” rating in a report on Friday, May 3rd. Robert W. Baird increased their price target on shares of Twist Bioscience from $39.00 to $40.00 and gave the stock an “outperform” rating in a report on Friday, May 3rd. Scotiabank increased their target price on shares of Twist Bioscience from $43.00 to $48.00 and gave the company a “sector outperform” rating in a report on Monday, May 6th. Finally, TD Cowen increased their target price on shares of Twist Bioscience from $55.00 to $65.00 and gave the company a “buy” rating in a report on Thursday, June 13th.

Insider Buying and Selling at Twist Bioscience

In other Twist Bioscience news, CEO Emily M. Leproust sold 4,163 shares of the firm’s stock in a transaction dated Friday, May 3rd. The shares were sold at an average price of $37.13, for a total transaction of $154,572.19. Following the completion of the sale, the chief executive officer now directly owns 509,986 shares in the company, valued at approximately $18,935,780.18. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other news, CEO Emily M. Leproust sold 4,163 shares of Twist Bioscience stock in a transaction that occurred on Friday, May 3rd. The shares were sold at an average price of $37.13, for a total value of $154,572.19. Following the completion of the sale, the chief executive officer now directly owns 509,986 shares in the company, valued at $18,935,780.18. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Paula Green sold 910 shares of Twist Bioscience stock in a transaction that occurred on Friday, May 3rd. The stock was sold at an average price of $37.13, for a total transaction of $33,788.30. Following the completion of the sale, the senior vice president now owns 91,511 shares of the company’s stock, valued at $3,397,803.43. The disclosure for this sale can be found here. In the last ninety days, insiders sold 17,163 shares of company stock worth $666,151. 3.92% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Twist Bioscience

A number of institutional investors and hedge funds have recently bought and sold shares of TWST. ARK Investment Management LLC boosted its position in shares of Twist Bioscience by 6.3% during the fourth quarter. ARK Investment Management LLC now owns 7,213,257 shares of the company’s stock valued at $265,881,000 after buying an additional 427,274 shares during the period. Artisan Partners Limited Partnership boosted its position in shares of Twist Bioscience by 111.3% during the fourth quarter. Artisan Partners Limited Partnership now owns 3,723,305 shares of the company’s stock valued at $137,241,000 after buying an additional 1,961,621 shares during the period. Sumitomo Mitsui Trust Holdings Inc. boosted its position in shares of Twist Bioscience by 2.9% during the fourth quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 3,583,443 shares of the company’s stock valued at $132,086,000 after buying an additional 99,511 shares during the period. Nikko Asset Management Americas Inc. boosted its position in shares of Twist Bioscience by 2.9% during the fourth quarter. Nikko Asset Management Americas Inc. now owns 3,583,443 shares of the company’s stock valued at $131,835,000 after buying an additional 99,511 shares during the period. Finally, Dimensional Fund Advisors LP boosted its position in shares of Twist Bioscience by 29.0% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,267,708 shares of the company’s stock valued at $46,732,000 after buying an additional 284,884 shares during the period.

Twist Bioscience Trading Up 4.6 %

Shares of TWST stock opened at $50.97 on Friday. The stock has a market capitalization of $2.97 billion, a P/E ratio of -15.17 and a beta of 1.78. The firm’s 50 day moving average is $41.89 and its 200 day moving average is $37.52. Twist Bioscience has a 12 month low of $14.42 and a 12 month high of $55.26.

Twist Bioscience (NASDAQ:TWST) last posted its earnings results on Thursday, May 2nd. The company reported ($0.79) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.84) by $0.05. Twist Bioscience had a negative net margin of 69.24% and a negative return on equity of 31.61%. The business had revenue of $75.30 million for the quarter, compared to analysts’ expectations of $70.70 million. During the same period in the prior year, the company posted ($1.06) EPS. The business’s revenue for the quarter was up 25.1% compared to the same quarter last year. On average, equities analysts predict that Twist Bioscience will post -3.08 EPS for the current year.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.